BioSyent Announces Renewal of Normal Course Issuer Bid

Executive Summary

• BioSyent Inc. received TSX‑V acceptance of its Notice of Intention to commence a Normal Course Issuer Bid, allowing purchase of up to 800,000 common shares (≈7.1% of outstanding shares).
• The NCIB runs from December 19 2025 through December 18 2026, with a maximum of 225,245 shares purchasable in any 30‑day period.
• Shares repurchased under the NCIB will be funded from cash reserves; most will be cancelled, with a limited portion held in trust for future RSU issuances.

Key Details

• Authorized Purchase Amount: Up to 800,000 common shares (≈7.1% of total outstanding as of Dec 15 2025).
• NCIB Period: Commences 19 Dec 2025; terminates 18 Dec 2026 (or earlier if purchase limit reached).
• 30‑Day Purchase Cap: 225,245 shares per 30‑day window (≈2% of total outstanding).
• Funding Source: Entirely from the Company’s cash reserves.
• Share Treatment: Majority of repurchased shares will be cancelled; a limited number retained in trust for future RSU plan issuances.
• Broker Arrangement: Automatic share purchase plan with Raymond James Ltd. to enable purchases during pre‑determined blackout periods; otherwise, purchases at senior management’s discretion.
• Historical Repurchases:
• Total of 3,112,525 shares repurchased and cancelled under prior NCIBs (Dec 10 2018 – Dec 15 2025) at an average price of $7.14 per share.
• Most recent NCIB period (19 Dec 2024 – 15 Dec 2025): 124,500 shares repurchased and cancelled at an average price of $11.21 per share.
• Outstanding Shares: 11,262,282 common shares as of the press release date.

Notable Quotes

• “BioSyent believes that the Shares may from time to time trade in a price range that does not adequately reflect the value of the Shares… purchase of Shares … would be an appropriate use of corporate funds in light of potential benefits to remaining shareholders.” – René C. Goehrum, President and CEO

Materiality Assessment: Material – Neutral (the announcement provides material information about future share repurchase activity that could affect shareholder equity but does not convey a positive or negative earnings impact).